This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
Responding to unmet needs for metastatic castration-resistant prostate cancer

Congress highlights - ASCO GU 2023

Read time: 40 mins
Last updated:2nd Mar 2023
Published:22nd Feb 2023

ASCO GU 2023: focus on mCRPC

PARP inhibitors: where do we go from here?

By Dawn O’Shea

With PARP inhibitors (PARPIs) now firmly established in the treatment of metastatic castration-resistant prostate cancer (mCRPC), questions remain to be answered as to how PARPIs should fit into the treatment paradigm and which patients should receive them.

Don’t miss the latest developments in mCRPC from ASCO GU 2023 with exclusive coverage from Medthority

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Recommendations on sequencing mCRPC therapies

By Dawn O’Shea

As the therapeutic armamentarium for metastatic castration-resistant prostate cancer (mCRPC) continues to grow, the burning question is, what is the optimal sequence for first-, second- and third-line settings to deliver the maximum benefit to patients?

That was the dilemma addressed by Dr Silke Gillessen, from the Oncology Institute of Southern Switzerland, at this year’s ASCO Genitourinary Symposium3.

“The most important factor in the choice of first-line treatment for mCRPC is what treatment the patient received in the hormone sensitive setting,” she said.

Don’t miss the latest developments in mCRPC from ASCO GU 2023 with exclusive coverage from Medthority

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

New therapeutic targets and concepts for mCRPC

By Dawn O’Shea

Intratumour myeloid cells, T cell exhaustion and metabolic dependencies are just some of a myriad of the new therapeutic targets that are being explored for the treatment of prostate cancer, presentations at the 2023 ASCO Genitourinary Symposium showed. The data suggest a wave of new therapies may be on the horizon.

With such an array of novel therapies under investigation, Johann Sebastian de Bono from University College London Cancer Institute, gave an overview of new targets and new concepts for the treatment of prostate cancer5.

“Selective tumour cell death remains the ‘Holy Grail’ and this is a rapidly burgeoning research space,” he said.

Targets that are currently being explored include androgen receptor (AR) gene splicing, apoptosis inhibition, novel synthetic lethal strategies, metabolic dependencies, epigenetic remodelling, and novel immunotherapy strategies.

Don’t miss the latest developments in mCRPC from ASCO GU 2023 with exclusive coverage from Medthority

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Welcome: